Research programme: engineered toxin bodies - Bristol Myers Squibb/Molecular Templates
Alternative Names: ETBs - Bristol Myers Squibb/Molecular TemplatesLatest Information Update: 28 Mar 2025
At a glance
- Originator Bristol-Myers Squibb; Molecular Templates
- Class Antineoplastics; Bacterial toxins; Drug conjugates; Immunoglobulin fragments; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action Cell death stimulants; Protein synthesis inhibitors; Proto-oncogene protein c-kit expression inhibitors; TROP2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 01 Apr 2024 Bristol-Myers Squibb plans to terminates its licence for engineered toxin body effective on June 13, 2024
- 12 Apr 2022 Pharmacodynamics data from a preclinical studies in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)